Copy
View this email in your browser

Welcome to the AMYPAD newsletter!

Dear friends and colleagues,

Frederik Barkhof

Hope this message finds you well before the holiday period despite the pandemic. I am thrilled that - COVID notwithstanding - we have managed to successfully complete the enrolment of the AMYPAD Diagnostic and Patient Management Study (DPMS), thanks to the great efforts of all of you! We are now anxiously awaiting the results of the primary endpoint, which we hope to collect early next year with results before the summer.
 
I personally have good memories of our general assembly meeting we had in early October. Despite the challenges of an online meeting, I think we had a good exchange of thoughts and information across the project and work packages. I hope you enjoyed the meeting like we did and felt sufficiently engaged. Our IMI project officer Elisabetta Vaudano was very positive and we value her engagement and continued support.
 
As you noticed, we have been working hard to collect the necessary data on scientific progress and financial information to complete the fourth year report which has been submitted earlier this week. This information will allow us to submit the request for a (no-cost) extension to make up for the delays suffered and hopefully concluded the AMYPAD Prognostic and Natural History Study (PNHS) study as much as possible.
 
I expect 2021 to be an exciting year for AMYPAD and especially the PNHS. Fortunately some sites are still able to include new subjects and we expect recruitment to pick up substantially next year. By then, data-integration across the parent cohorts should also be enacted, allowing pooling of all data including several historical data-points to be uncovered.
 
Whatever scientific rewards to New Year may bring us, I wish you all the best personally with sufficient time for your loved ones and good health.

This electronic newsletter will be published quarterly and be accessible via the AMYPAD website (www.amypad.eu). In this issue, we present you the AMYPAD General Assembly Meeting and an update on recruitment. In addition, you can also get to know two AMYPAD collaborators, Agneta Nordberg and Pieter Jelle Visser who share some of their expectations with us.

Frederik Barkhof
AMYPAD Coordinator

In the spotlight - AMYPAD GA Meeting
On 8 and 9 October, the “Amyloid imaging to Prevent Alzheimer’s disease” (AMYPAD) consortium held its annual General Assembly as a virtual meeting. Frederik Barkhof and Gill Farrar, coordinators of the AMYPAD project, kicked off the General Assembly by welcoming over 100 attendees (exceeding any of our past General Assembly meetings).

Due to the coronavirus pandemic situation, like so many other events, AMYPAD opted to hold the meeting in an online format. It was an invigorating General Assembly meeting to review the progress made so far, plan for the last year of the project and discuss the future of AMYPAD. The meeting was a success, but we hope that the next General Assembly will be a face-to-face meeting.
 
Read More

Meet some of the AMYPAD collaborators

Interview with Agneta Nordberg

As a professor in clinical neuroscience at Karolinska Institutet and senior consultant at the memory clinic at Karolinska university hospital I am PI for the AMYPAD study in Stockholm. I am responsible for the WP3 (Diagnostic and patient management study) in Stockholm where we have finalised the recruitment of patients at the memory clinic and amyloid PET scanning and clinical follow-ups are ongoing...
 
Read More
 

Interview with Pieter Jelle Visser

Since 1st November 2020, I am academic co-lead of the AMYPAD WP4 (Risk stratification: natural history and enrichment strategies). I have already been sideways involved in WP4 as the PI of the EMIF preclinAD study, which is a parent cohort in the AMYPAD Prognostic and Natural History Study (PNHS) that now receives a repeated amyloid PET scans four years after baseline. My main task in WP4 is to supervise the data integration of the EPAD and parent cohorts...
 
Read More
 

Highlights of the past quarter

AMYPAD announces end of recruitment in the Diagnostic and Patient Management Study


On 1 November, the AMYPAD members announced the completion of the enrolment of research participants in its Diagnostic and Patient Management Study (DPMS).

The first participant was recruited in Geneva, Switzerland in May 2018. The study recruited individuals with Subjective Cognitive Decline plus (SCD+), Mild Cognitive Impairment (MCI), and dementia from eight European study centers in Amsterdam (Netherlands), Barcelona (Spain), Cologne (Germany), Geneva (Switzerland), Lausanne (Switzerland), London (United Kingdom), Stockholm (Sweden) and Toulouse (France).  

Despite the negative impact of COVID-19, the project succeeded in recruiting 844 of the planned 900 participants when recruitment was formally ended on 30 October. A total of 245 people with SCD, 342 with MCI and 258 with dementia had been enrolled and will continue to be followed as scheduled.

According to Prof. Giovanni Frisoni, group leader of the laboratory of neuroimaging of aging at the University of Geneva: “This is a truly exceptional result. Despite being hit by 2 waves of the COVID-19 pandemic, participating memory clinics were able to recruit as many as 94% of the target group size. Even a once-in-a-century pandemic was unable to stop the AMYPAD Diagnostic and Patient Management Study.”

To date, 724 scans have been performed (including 53 repeat scans) and sites are now focusing on completing all remaining scans and collecting all data for the already enrolled patients. Results on the primary endpoint are expected in mid-2021.

The consortium would like to thank all study centers for their excellent support, hard work and high flexibility during these difficult times, as well as all research participants for their willingness to participate in the project and increase our understanding of the role and impact of amyloid imaging in the diagnosis and management of Alzheimer’s disease.
 
Read More

AMYPAD around the world

Alzheimer Europe Conference
20-22 October 2020


The 30th Alzheimer Europe Conference “Dementia in a changing world” was held online from 20-22 October. Almost 800 participants, from 42 countries, attended the conference. Gill Farrar illustrated how the AMYPAD project is actively engaging with European regulators...
 
Read More

Upcoming event


- 15th International Conference on Alzheimer's & Parkinson's Diseases (AD/PD)
9-14 March 2021, virtual event
 

What we are reading - AMYPAD latest publications

[11C]PIB amyloid quantification: effect of reference region selection
 

Amyloid-PET and 18 F-FDG-PET in the diagnostic investigation of Alzheimer’s disease and other dementias

Subscribe to our newsletter so that you don't miss future updates about the AMYPAD project!
Subscribe
Twitter
Website
Email
Acknowledgement.
The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives the support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

Disclaimer
This newsletter reflects the views of the AMYPAD Consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.
Copyright ©2017 AMYPAD, All rights reserved.

Our mailing address is:
info@amypad.org

 






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
AMYPAD · 14, rue de Dicks · Luxembourg 1417 · Luxembourg

Email Marketing Powered by Mailchimp